Urinary proteomic profiling for diagnostic bladder cancer biomarkers

References

• Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer83(1), 18–29 (1999).
   PubMed Web of Science ®Google Scholar
• Aben KK, Kiemeney LA. Epidemiology of bladder cancer. Eur. Urol.36(6), 660–672 (1999).
   PubMedGoogle Scholar
• Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J. Urol.164(3 Pt 1), 680–684 (2000).
   PubMed Web of Science ®Google Scholar
• Rife CC, Farrow GM, Utz DC. Urine cytology of transitional cell neoplasms. Urol. Clin. North Am.6(3), 599–612 (1979).
   PubMed Web of Science ®Google Scholar
• Cajulis RS, Haines GK 3rd, Frias-Hidvegi D, McVary K, Bacus JW. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn. Cytopathol.13(3), 214–223; discussion 224 (1995).
   PubMed Web of Science ®Google Scholar
• Hautmann S, Toma M, Lorenzo Gomez MF et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur. Urol.46(4), 466–471 (2004).
   PubMed Web of Science ®Google Scholar
• Giannopoulos A, Manousakas T, Mitropoulos D et al. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors. Urology55(6), 871–875 (2000).
   PubMed Web of Science ®Google Scholar
• Babjuk M, Soukup V, Pesl M et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology71(4), 718–722 (2008).
   PubMed Web of Science ®Google Scholar
• Schroeder GL, Lorenzo-Gomez MF, Hautmann SH et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J. Urol.172(3), 1123–1126 (2004).
   PubMed Web of Science ®Google Scholar
• Schaub S, Wilkins J, Weiler T et al. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int.65(1), 323–332 (2004).
   PubMed Web of Science ®Google Scholar
• Theodorescu D, Wittke S, Ross MM et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol.7(3), 230–240 (2006).
   PubMed Web of Science ®Google Scholar
• Schiffer E, Mischak H, Novak J. High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics6(20), 5615–5627 (2006).
   PubMed Web of Science ®Google Scholar
• Oh J, Pyo JH, Jo EH et al. Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics4(11), 3485–3497 (2004).
   PubMed Web of Science ®Google Scholar
• Bueler MR, Wiederkehr F, Vonderschmitt DJ. Electrophoretic, chromatographic and immunological studies of human urinary proteins. Electrophoresis16(1), 124–134 (1995).
   PubMed Web of Science ®Google Scholar
• Marshall T, Williams K. Two-dimensional electrophoresis of human urinary proteins following concentration by dye precipitation. Electrophoresis17(7), 1265–1272 (1996).
   PubMed Web of Science ®Google Scholar
• Thongboonkerd V, McLeish KR, Arthur JM, Klein JB. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int.62(4), 1461–1469 (2002).
   PubMed Web of Science ®Google Scholar
• Heine G, Raida M, Forssmann WG. Mapping of peptides and protein fragments in human urine using liquid chromatography-mass spectrometry. J. Chromatogr. A776(1), 117–124 (1997).
   PubMed Web of Science ®Google Scholar
• Wittke S, Fliser D, Haubitz M et al. Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J. Chromatogr. A1013(1–2), 173–181 (2003).
   PubMed Web of Science ®Google Scholar
• Pieper R, Gatlin CL, McGrath AM et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics4(4), 1159–1174 (2004).
   PubMed Web of Science ®Google Scholar
• Sun W, Li F, Wu S et al. Human urine proteome analysis by three separation approaches. Proteomics5(18), 4994–5001 (2005).
   PubMed Web of Science ®Google Scholar
• Castagna A, Cecconi D, Sennels L et al. Exploring the hidden human urinary proteome via ligand library beads. J. Proteome Res.4(6), 1917–1930 (2005).
   PubMed Web of Science ®Google Scholar
• Tyan YC, Guo HR, Liu CY, Liao PC. Proteomic profiling of human urinary proteome using nano-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal. Chim. Acta.579(2), 158–176 (2006).
   PubMedGoogle Scholar
• Coon JJ, Zurbig P, Dakna M et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin. Appl.2, 964–973 (2008).
   PubMed Web of Science ®Google Scholar
• Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol.7(9), R80 (2006).
   PubMed Web of Science ®Google Scholar
• Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. Mol. Cell. Proteomics.5(10), 1760–1771 (2006).
   PubMed Web of Science ®Google Scholar
• Gonzales PA, Pisitkun T, Hoffert JD, T et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J. Am. Soc. Nephrol.20(2), 363–379 (2009).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Langham RG, Ronco P, Knepper MA, Thongboonkerd V. Towards standard protocols and guidelines for urine proteomics: a report on the Human Kidney and Urine Proteome Project (HKUPP) symposium and workshop, 6 October 2007, Seoul, Korea and 1 November 2007, San Francisco, CA, USA. Proteomics8(11), 2156–2159 (2008).
   PubMed Web of Science ®Google Scholar
• Vlahou A, Schanstra J, Frokiaer J et al. Establishment of a European Network for Urine and Kidney Proteomics. J. Proteomics71(4), 490–492 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Y, Adachi J et al. MAPU: Max-Planck Unified database of organellar, cellular, tissue and body fluid proteomes. Nucleic Acids Res.35(Database issue), D771–D779 (2007).
   Google Scholar
• Li SJ, Peng M, Li H et al. Sys-BodyFluid: a systematical database for human body fluid proteome research. Nucleic Acids Res.37(Database issue), D907–D912 (2009).
   PubMed Web of Science ®Google Scholar
• Tantipaiboonwong P, Sinchaikul S, Sriyam S, Phutrakul S, Chen ST. Different techniques for urinary protein analysis of normal and lung cancer patients. Proteomics5(4), 1140–1149 (2005).
   PubMed Web of Science ®Google Scholar
• Nabi G, N’Dow J, Hasan TS, Booth IR, Cash P. Proteomic analysis of urine in patients with intestinal segments transposed into the urinary tract. Proteomics5(6), 1729–1733 (2005).
   PubMedGoogle Scholar
• Thongboonkerd V, Chutipongtanate S, Kanlaya R. Systematic evaluation of sample preparation methods for gel-based human urinary proteomics: quantity, quality, and variability. J. Proteome Res.5(1), 183–191 (2006).
   PubMed Web of Science ®Google Scholar
• Getzenberg RH, Konety BR, Oeler TA et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res.56(7), 1690–1694 (1996).
   PubMed Web of Science ®Google Scholar
• Myers-Irvin JM, Landsittel D, Getzenberg RH. Use of the novel marker BLCA-1 for the detection of bladder cancer. J. Urol.174(1), 64–68 (2005).
   PubMed Web of Science ®Google Scholar
• Rasmussen HH, Orntoft TF, Wolf H, Celis JE. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J. Urol.155(6), 2113–2119 (1996).
   PubMed Web of Science ®Google Scholar
• Irmak S, Tilki D, Heukeshoven J et al. Stage-dependent increase of orosomucoid and zinc-α2-glycoprotein in urinary bladder cancer. Proteomics5(16), 4296–4304 (2005).
   PubMed Web of Science ®Google Scholar
• Orenes-Pinero E, Corton M, Gonzalez-Peramato P et al. Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J. Proteome Res.6(11), 4440–4448 (2007).
   PubMed Web of Science ®Google Scholar
• Saito M, Kimoto M, Araki T et al. Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. Eur. Urol.48(5), 865–871 (2005).
   PubMed Web of Science ®Google Scholar
• Vlahou A, Schellhammer PF, Mendrinos S et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol.158(4), 1491–1502 (2001).
   PubMed Web of Science ®Google Scholar
• Mueller J, von Eggeling F, Driesch D et al. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur. Urol.47(6), 885–893; discussion 893–884 (2005).
   PubMed Web of Science ®Google Scholar
• Holterman DA, Diaz JI, Blackmore PF et al. Overexpression of α-defensin is associated with bladder cancer invasiveness. Urol. Oncol.24(2), 97–108 (2006).
   PubMed Web of Science ®Google Scholar
• Kolch W, Neususs C, Pelzing M, Mischak H. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom. Rev.24(6), 959–977 (2005).
   PubMed Web of Science ®Google Scholar
• Ye B, Skates S, Mok SC et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res.12(2), 432–441 (2006).
   PubMed Web of Science ®Google Scholar
• Wang Y, Ao X, Vuong H et al. Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach. J. Proteome Res.7(10), 4313–4325 (2008).
   PubMedGoogle Scholar
• Patwa TH, Wang Y, Miller FR et al. A novel phosphoprotein analysis scheme for assessing changes in premalignant and malignant breast cell lines using 2D liquid separations, protein microarrays and tandem mass spectrometry. Proteomics Clin. Appl.3(1), 51–66 (2008).
   PubMedGoogle Scholar
• Kreunin P, Yoo C, Urquidi V, Lubman DM, Goodison S. Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry. Cancer Genomics Proteomics4(5), 329–339 (2007).
   PubMedGoogle Scholar
• Kreunin P, Zhao J, Rosser C et al. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J. Proteome Res.6(7), 2631–2639 (2007).
   PubMed Web of Science ®Google Scholar
• Tian M, Cui YZ, Song GH et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer8, 241 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao J, Patwa TH, Qiu W et al. Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. J. Proteome Res.6(5), 1864–1874 (2007).
   PubMed Web of Science ®Google Scholar
• Wang L, Li F, Sun W et al. Concanavalin A-captured glycoproteins in healthy human urine. Mol. Cell. Proteomics5(3), 560–562 (2006).
   PubMed Web of Science ®Google Scholar
• Feng S, Yang N, Pennathur S, Goodison S, Lubman DM. Enrichment of glycoproteins using nanoscale chelating concanavalin A monolithic capillary chromatography. Anal Chem.81(10), 3776–3783 (2009).
   PubMed Web of Science ®Google Scholar
• Schiffer E, Vlahou A, Petrolekas et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin. Cancer Res.15(15), 4935–4943 (2009).
   PubMed Web of Science ®Google Scholar
• Habuchi T, Marberger M, Droller et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology66(6 Suppl. 1), 64–74 (2005).
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Habuchi T, Grossman HB et al. Bladder tumor markers beyond cytology: international Consensus Panel on bladder tumor markers. Urology66(6 Suppl. 1), 55–63 (2005).
   PubMedGoogle Scholar
• Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet374(9685), 239–249 (2009).
   PubMed Web of Science ®Google Scholar
• Sun Y, Goodison S, Li J, Liu L, Farmerie W. Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics23(1), 30–37 (2007).
   PubMed Web of Science ®Google Scholar
• Sun Y, Urquidi V, Goodison S. Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach. Breast Cancer Res. Treat. DOI: 10.1007/s10549-009-0365-6 (2009) (Epub ahead of print).
   Google Scholar
• Sun Y, Goodison S. Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate69(10), 1119–1127 (2009).
   PubMedGoogle Scholar
• Hijazi A, Devonec M, Bouvier R, Revillard JP. Flow cytometry study of cytokeratin 18 expression according to tumor grade and deoxyribonucleic acid content in human bladder tumors. J. Urol.141(3), 522–526 (1989).
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Rodriguez-Martinez JJ, Barmadah SE et al. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur. Urol.51(5), 1267–1274 (2007).
   PubMed Web of Science ®Google Scholar
• Olsson H, Zackrisson B. ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J. Urol. Nephrol.35(4), 280–282 (2001).
   PubMedGoogle Scholar
• Mian C, Pycha A, Wiener H et al. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J. Urol.161(5), 1486–1489 (1999).
   PubMed Web of Science ®Google Scholar
• Miyanaga N, Akaza H, Tsukamoto S et al. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection. Int. J. Clin. Oncol.8(6), 369–373 (2003).
   PubMedGoogle Scholar
• Shariat SF, Bolenz C, Godoy G et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J. Urol.182(1), 78–84; discussion 84 (2009).
   PubMed Web of Science ®Google Scholar
• Grossman HB, Soloway M, Messing E et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA295(3), 299–305 (2006).
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur. Urol.47(6), 736–748 (2005).
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB. Are there molecular signatures for predicting bladder cancer prognosis? J. Urol.176(6 Pt 1), 2347–2348 (2006).
   PubMedGoogle Scholar
• Svatek RS, Herman MP, Lotan Y et al. Soluble Fas – a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer106(8), 1701–1707 (2006).
   PubMed Web of Science ®Google Scholar
• Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol.154(6), 2706–2713 (1995).
   PubMed Web of Science ®Google Scholar
• Van Le TS, Miller R, Barder T et al. Highly specific urine-based marker of bladder cancer. Urology66(6), 1256–1260 (2005).
   PubMed Web of Science ®Google Scholar
• Konety BR, Nguyen TS, Brenes G et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J. Urol.164(3 Pt 1), 634–639 (2000).
   PubMed Web of Science ®Google Scholar
• Uhlen M, Bjorling E, Agaton C et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteomics4(12), 1920–1932 (2005).
   PubMed Web of Science ®Google Scholar
• Kersey PJ, Duarte J, Williams A et al. The International Protein Index: an integrated database for proteomics experiments. Proteomics4(7), 1985–1988 (2004).
   PubMed Web of Science ®Google Scholar